Unleashing the Potential of ADCs
Antibody-drug conjugates have the potential to become the backbone of future oncology therapy, however earlier generations of ADCs continue to face key challenges in safety and efficacy.
Hummingbird Bioscience has developed a 4th generation ADC platform to engineer potentially best-in-class ADCs that:
- Address payload resistance
- Optimize payload delivery & tumor specificity
- Maximize anti-tumor cytotoxic potential
Callio Therapeutics has in-licensed the ADC platform technology for use in the oncology field.
Hummingbird Bioscience has developed a proprietary, differentiated linker technology that enables next-generation dual-payload conjugates. Our technology is capable of producing stable, developable conjugates across various formats.
- Targeting format agnostic – conjugation possible to antibodies, peptides, fragments and more
- Stable conjugates – designed for manufacturability, hydrophilicity, and non-immunogenicity
- Payload and DAR flexibility – applicable to a broad range of payloads, the linker enables both single and dual payload combinations from low to high DAR
